A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: King Faisal Specialist Hospital & Research Center
• Treatments: Bevacizumab; Camptothecin; Capecitabine; Irinotecan; Oxaliplatin

Criteria

Inclusion Criteria:

• Patients with diagnosed Metastatic Colorectal Cancer

Exclusion Criteria:

• Patients with diagnosis other than Metastatic Colorectal Cancer